A Lauter1, K Triantafyllias2, R Leiß1, C Amberger3, J Engels4, M Hesse5, M Jendro6, J Gilly7, M-L Stadelmann8, W Ziese9, D Wollschläger10, M Dreher1, B Pfeiff2, J Weinmann-Menke1, T Panholzer10, A Schwarting11,12. 1. Schwerpunkt Rheumatologie und klinische Immunologie, Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Langenbeckstr. 1, 55131, Mainz, Deutschland. 2. ACURA Rheumakliniken Rheinland-Pfalz GmbH, Bad Kreuznach, Deutschland. 3. Rheumatologische Schwerpunktpraxis, Bad Neuenahr, Deutschland. 4. Rheumatologische Schwerpunktpraxis, Koblenz, Deutschland. 5. Rheumatologische Schwerpunktpraxis, Bad Kreuznach, Deutschland. 6. Rheumatologische Schwerpunktpraxis, Kaiserslautern, Deutschland. 7. Rheumatologische Schwerpunktpraxis, Landau, Deutschland. 8. Rheumatologische Schwerpunktpraxis, Wittlich, Deutschland. 9. Rheumatologische Schwerpunktpraxis, Trier, Deutschland. 10. Institut für Medizinische Biometrie, Epidemiologie und Informatik, Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, Deutschland. 11. Schwerpunkt Rheumatologie und klinische Immunologie, Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Langenbeckstr. 1, 55131, Mainz, Deutschland. schwarting@uni-mainz.de. 12. ACURA Rheumakliniken Rheinland-Pfalz GmbH, Bad Kreuznach, Deutschland. schwarting@uni-mainz.de.
Abstract
BACKGROUND/ OBJECTIVE: The majority of patients in Germany miss out on the necessity of early diagnosis and initiation of therapy for rheumatoid arthritis (RA) caused by considerable structural deficits in the health care system. The challenge is to reconcile the individual demand for the best possible therapy result with a sustainable expenditure of resources. METHODS: The cross-sectoral regional care network ADAPTHERA aims to improve early RA diagnosis and treatment in Rhineland-Palatinate. The retrospective triage analyses of suspected early onset RA patients was performed by tracing the selection process of all available enquiries (n = 1045). For analysis of the clinical course of the disease, a subset comprising 143 patients with a minimum observation time of 12 months (5 consecutive visits) was available. Clinical and laboratory parameters were collected quarter yearly, self-administered questionnaires were filled out and the treatment was adapted if necessary. RESULTS: A total of 454 patients were included. The mean waiting time was 23.9 (SD = 18) days. The mean observation period in the subcohort was 29.2 (SD = 12.7) months, with about 50% of the patients presenting within 3 months. Almost 75% of the patients were in remission after 2 years. A sustained remission could be described for 74.8% (6 months) and 53.5% (12 months), respectively. Especially patients with rapid remission induction benefited in terms of longer remissions (p = 0.03). A very early stage of the disease (VERA) was associated with a rarely necessary biologic therapy (p = 0.022). DISCUSSION: The approach of a supply network is not a panacea, but it might improve healthcare for patients with early onset RA. In order to minimize resource utilization, a pinpoint referral and accurate triage of potential cases are crucial.
BACKGROUND/ OBJECTIVE: The majority of patients in Germany miss out on the necessity of early diagnosis and initiation of therapy for rheumatoid arthritis (RA) caused by considerable structural deficits in the health care system. The challenge is to reconcile the individual demand for the best possible therapy result with a sustainable expenditure of resources. METHODS: The cross-sectoral regional care network ADAPTHERA aims to improve early RA diagnosis and treatment in Rhineland-Palatinate. The retrospective triage analyses of suspected early onset RApatients was performed by tracing the selection process of all available enquiries (n = 1045). For analysis of the clinical course of the disease, a subset comprising 143 patients with a minimum observation time of 12 months (5 consecutive visits) was available. Clinical and laboratory parameters were collected quarter yearly, self-administered questionnaires were filled out and the treatment was adapted if necessary. RESULTS: A total of 454 patients were included. The mean waiting time was 23.9 (SD = 18) days. The mean observation period in the subcohort was 29.2 (SD = 12.7) months, with about 50% of the patients presenting within 3 months. Almost 75% of the patients were in remission after 2 years. A sustained remission could be described for 74.8% (6 months) and 53.5% (12 months), respectively. Especially patients with rapid remission induction benefited in terms of longer remissions (p = 0.03). A very early stage of the disease (VERA) was associated with a rarely necessary biologic therapy (p = 0.022). DISCUSSION: The approach of a supply network is not a panacea, but it might improve healthcare for patients with early onset RA. In order to minimize resource utilization, a pinpoint referral and accurate triage of potential cases are crucial.
Entities:
Keywords:
Early RA; Healthcare; Remission; Waiting time; Window of opportunity
Authors: M Vermeer; H H Kuper; H J Bernelot Moens; K W Drossaers-Bakker; A E van der Bijl; P L C M van Riel; M A F J van de Laar Journal: Arthritis Care Res (Hoboken) Date: 2013-08 Impact factor: 4.794
Authors: A Zink; J Braun; E Gromnica-Ihle; D Krause; H J Lakomek; W Mau; U Müller-Ladner; J Rautenstrauch; C Specker; M Schneider Journal: Z Rheumatol Date: 2017-04 Impact factor: 1.372
Authors: Hèctor Corominas; Javier Narváez; César Díaz-Torné; Georgina Salvador; María Eugenia Gomez-Caballero; Diana de la Fuente; Ester Campoy; Daniel Roig-Vilaseca; Teresa Clavaguera; Rosa Morlà; Vicenç Torrente-Segarra; Xavier Arasa; José Alfredo Gomez-Puerta; Ingrid Möller; Cayetano Alegre; Eduard Graell; Andrés Ponce; María Pilar Lisbona; Carolina Pérez-Garcia; Ramon Fíguls; Elena Sirvent; Violan Poca; Raimon Sanmartí Journal: Reumatol Clin Date: 2015-09-08
Authors: Josef S Smolen; Robert Landewé; Johannes Bijlsma; Gerd Burmester; Katerina Chatzidionysiou; Maxime Dougados; Jackie Nam; Sofia Ramiro; Marieke Voshaar; Ronald van Vollenhoven; Daniel Aletaha; Martin Aringer; Maarten Boers; Chris D Buckley; Frank Buttgereit; Vivian Bykerk; Mario Cardiel; Bernard Combe; Maurizio Cutolo; Yvonne van Eijk-Hustings; Paul Emery; Axel Finckh; Cem Gabay; Juan Gomez-Reino; Laure Gossec; Jacques-Eric Gottenberg; Johanna M W Hazes; Tom Huizinga; Meghna Jani; Dmitry Karateev; Marios Kouloumas; Tore Kvien; Zhanguo Li; Xavier Mariette; Iain McInnes; Eduardo Mysler; Peter Nash; Karel Pavelka; Gyula Poór; Christophe Richez; Piet van Riel; Andrea Rubbert-Roth; Kenneth Saag; Jose da Silva; Tanja Stamm; Tsutomu Takeuchi; René Westhovens; Maarten de Wit; Désirée van der Heijde Journal: Ann Rheum Dis Date: 2017-03-06 Impact factor: 19.103
Authors: K Kumar; E Daley; D M Carruthers; D Situnayake; C Gordon; K Grindulis; C D Buckley; F Khattak; K Raza Journal: Rheumatology (Oxford) Date: 2007-06-19 Impact factor: 7.580
Authors: K Benesova; H-M Lorenz; V Lion; A Voigt; A Krause; O Sander; M Schneider; M Feuchtenberger; A Nigg; J Leipe; S Briem; E Tiessen; F Haas; M Rihl; D Meyer-Olson; X Baraliakos; J Braun; A Schwarting; M Dreher; T Witte; G Assmann; K Hoeper; R E Schmidt; P Bartz-Bazzanella; M Gaubitz; C Specker Journal: Z Rheumatol Date: 2019-10 Impact factor: 1.372